GlassScriptPhysician profile
Vijaykumar Karumbunathan
NPI 1174589386
$2,378.73
in general payments reported to CMS, 2019-2025
22 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $29.07 · 2022: $34.46 · 2023: $184 · 2024: $782 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $308.03 | 2023-2025 | |
| Pfizer INC. | $278.67 | 2019-2025 | |
| Ucb, INC. | $231.03 | 2023-2025 | Rystiggo, Zilbrysq |
| Astrazeneca Pharmaceuticals LP | $190.22 | 2019-2025 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $175.45 | 2023-2025 | Rexulti |
| Scpharmaceuticals INC. | $148.82 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.01 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $120.84 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $120.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $97.15 | 2019-2025 | |
| Exact Sciences Corporation | $96.81 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $72.65 | 2022-2025 | Prolia, Evenity, Otezla |
| Merck Sharp & Dohme LLC | $68.94 | 2024-2025 | Verquvo |
| Astellas Pharma US INC | $65.30 | 2023-2025 | Veozah |
| Lundbeck LLC | $60.27 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.02 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.94 | 2024-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $36.31 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $32.73 | 2024 | |
| Lilly USA, LLC | $21.93 | 2025 | Kisunla |
| Ardelyx, INC. | $21.67 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $17.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijaykumar Karumbunathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.